Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

September 21, 2017

Study Completion Date

September 21, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Ga-68 labeled PSMA-11 PET

Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | Biotech Hunter | Biotech Hunter